Double-blind trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 82, Issue 6, 1999, Pages 535-541

  Berger, William E ^a,d   Fineman, Stanley M ^b   Lieberman, Phillip ^c   Miles, Robert M ^c  

^a Southern California Research   (United States)

^b Atlanta Allerg Immunol Res Found   (United States)

^c 27800 Medical Center ^*  (United States)

^d Allergy & Asthma Associates of Northern California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELASTINE; BECLOMETASONE DIPROPIONATE; LORATADINE;

ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REPRODUCIBILITY; SEASONAL VARIATION; SOMNOLENCE; TABLET; TASTE DISORDER;

EID: 0033039076     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63161-4     Document Type: Article

References (22)

1. 1, beta, and muscarinic receptor-binding sites. J Allergy Clin Immunol 1989;83: 771-776.
2. Hamasaki Y, Shafigeh M, Yamamoto S, et al. Inhibition of leukotriene synthesis by azelastine. Ann Allergy Asthma Immunol 1996;76:469-475.
3. 4 release and production by bronchial asthmatic eosinophils. Respir Res 1990;9:206-212.
4. Little MM, Casale TB. Azelastine inhibits IgE-mediated human basophil histamine release. J Allergy Clin Immunol 1989;83:862-865.
5. Morita Y, Ohshima Y, Akutagawa H, et al. Inhibitory effects of azelastine on Ca2+ influx, actin polymerization and release of eosinophil cationic protein of an eosinophilic leukaemia cell line EoL-1. Curr Med Res Opin 1993;13: 163-174.
6. Umeki S. Effects of antiallergic drugs on human neutrophil superoxide-generating NADPH oxidase. Biochem Pharmacol 1992;43:1109-1117.
7. Busse W, Randley B, Sedgwick J, Sofia RD. The effect of azelastine on neutrophil and eosinophil generation of superoxide. J Allergy Clin Immunol 1989;83:400-405.
8. Chand N, Nolan K, Diamantis W, Perhach JL Jr, Sofia RD. Inhibition of leukotriene (SRS-A)-mediated acute lung anaphylaxis by azelastine in guinea pigs. Allergy 1986;41: 473-478.
9. Chand N, Nolan K, Diamantis W, Sofia RD. Inhibition of aeroallergen-induced bronchial eosinophilia by azelastine in guinea pigs. Int Arch Allergy Immunol 1992;97:229-232.
10. Konno S, Asano K, Gonokami Y, et al. Effect of azelastine on endotoxin-induced airway hyperresponsiveness in mice. Int Arch Allergy Immunol 1995;108:292-297.
11. Shin MH, Baroody F, Proud D, et al. The effect of azelastine on the early allergic response. Clin Exp Allergy 1992;22:289-295.
12. Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol 1996; 98:1088-1096.
13. Weiler JM, Meltzer EO, Benson PM, et al. A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model. J Allergy Clin Immunol 1994;94: 972-980.
14. Meltzer EO, Weiler JM, Dockhorn RJ, et al. Azelastine nasal spray in the management of seasonal allergic rhinitis. Ann Allergy 1994;72:354-359.
15. Ratner PH, Findlay SR, Hampel F, et al. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol 1994;94:818-825.
16. Storms WW, Pearlman DS, Chervinsky P, et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis. Ear Nose Throat J 1994;73: 382-394.
17. LaForce C, Dockhorn RJ, Prenner BM, et al. Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996;76:181-188.
18. Baumgarten CR, Petzold U, Dokic D, et al. Modification of allergen-induced symptoms and mediator release by intranasal azelastine. J Pharmacol U Ther 1994;3:43-51.
19. Naclerio RM. Allergic rhinitis. N Engl J Med 1991;325:860-869.
20. Katayama S, Tsunoda H, Sakuma Y, et al. Effect of azelastine on the release and action of leukotriene C4 and D4. Int Arch Allergy Appl Immunol 1987; 83:284-289.
21. Chand N, Sofia RD. Azelastine - a novel in vivo inhibitor of leukotriene biosynthesis: a possible mechanism of action: a mini review. J Asthma 1995; 32:227-234.
22. Wang D, Smitz J, De Waele M, Clement P. Effect of topical applications of budesonide and azelastine on nasal symptoms, eosinophil count and mediator release in atopic patients after nasal allergen challenge during the pollen season. Int Arch Allergy Immunol 1997;114:185-192.